Nanomedicine
Medical applications of nanotechnology including drug delivery and diagnostics
Nanobiotix
Paris, France
Clinical-stage biotechnology company pioneering nanomedicine with first-in-class radioenhancers for cancer treatment
Arrowhead Research
Pasadena, United States
Biopharmaceutical company developing targeted RNAi therapeutics using proprietary TRiM platform
BIND Therapeutics
Cambridge, United States
BIND Therapeutics, founded in 2007 and based in Cambridge, Massachusetts, pioneered the Accurin platform of polymeric nanoparticles for targeted cancer drug delivery, representing one of the most advanced clinical applications of nanomedicine. With over $150 million in funding and 100-200 employees, BIND developed sophisticated nanotechnology designed to precisely deliver chemotherapy agents to tumor cells while minimizing systemic toxicity. The company emerged from groundbreaking research at MIT and Harvard on controlled drug delivery using biodegradable polymer nanoparticles. BIND's Accurin nanoparticles were engineered with extraordinary precision, incorporating multiple functional components: a biodegradable polymer core loaded with chemotherapy drugs, a protective hydrophilic polymer shell to evade immune system clearance, and targeting ligands that bind to specific molecules overexpressed on cancer cells. This multicomponent design addressed fundamental challenges in cancer treatment—delivering sufficient drug to tumors while avoiding damage to healthy tissues. The company's lead candidate, BIND-014, consisted of docetaxel chemotherapy encapsulated in nanoparticles displaying PSMA-targeting ligands, designed for prostate cancer treatment. BIND advanced multiple nanoparticle candidates through clinical trials, generating valuable data on nanomedicine performance in humans. The company's clinical programs demonstrated that carefully designed nanoparticles could alter drug biodistribution, enhance tumor accumulation, and potentially improve therapeutic indices. BIND employed sophisticated polymer chemistry and formulation sciences to create nanoparticles with controlled sizes (typically 50-100 nanometers), precise drug loading, and sustained release profiles. The company developed scalable manufacturing processes meeting pharmaceutical GMP standards—a significant achievement given the complexity of multi-functional nanoparticles. Throughout its existence, BIND contributed substantially to understanding how nanoparticle properties including size, surface chemistry, and targeting ligands influence biological fate and therapeutic efficacy. Despite promising preclinical data and successful clinical trial execution, BIND faced challenges common to nanomedicine development including complex regulatory pathways, high development costs, and difficulty demonstrating sufficient therapeutic advantages over existing treatments. In 2016, facing financial pressures, BIND was acquired by Pfizer, which subsequently discontinued the programs, highlighting the challenging economics of nanomedicine development. Nevertheless, BIND's legacy includes important contributions to nanomedicine science, demonstration that sophisticated nanoparticles can be manufactured at pharmaceutical scales, and clinical data advancing understanding of nanoparticle behavior in humans. The company's experience provides valuable lessons for the nanomedicine field regarding the gap between preclinical promise and clinical reality, the importance of selecting appropriate patient populations, and the need for compelling therapeutic differentiation to justify nanomedicine's inherent complexity.
Selecta Biosciences
Watertown, United States
Selecta Biosciences, Inc., founded in 2007 and based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company developing its proprietary ImmTOR nanoparticle platform to address a critical challenge in biologics therapy—unwanted immune responses that reduce treatment efficacy. Publicly traded on NASDAQ (SELB) with over $300 million in funding and 100-200 employees, Selecta has pioneered synthetic vaccine particles (SVP) that can selectively modulate immune responses, potentially enabling repeat administration of therapeutic proteins and gene therapies. The company emerged from research on how nanoparticle properties influence immune system activation, discovering that specific nanoparticle designs could induce immune tolerance rather than immunogenicity. Selecta's ImmTOR platform consists of biodegradable polymer nanoparticles incorporating immunomodulatory small molecules (typically rapamycin analogs) that are taken up by immune cells, inducing tolerance to co-administered therapeutic agents. This approach addresses a major limitation of protein therapeutics and gene therapies—the development of neutralizing antibodies that reduce or eliminate treatment efficacy with repeated dosing. For example, many patients with gout receiving enzyme replacement therapy develop anti-drug antibodies that neutralize the therapeutic enzyme, requiring treatment discontinuation. Selecta's lead program, SEL-212, combines ImmTOR nanoparticles with pegsiticase enzyme therapy for severe gout, with clinical trials demonstrating reduced immunogenicity and improved sustained therapeutic response. The company has expanded its platform to address immunogenicity challenges in gene therapy, where immune responses against viral vectors or therapeutic proteins can limit treatment durability. Selecta has established partnerships with major pharmaceutical companies including Sarepta Therapeutics and Asklepios BioPharmaceutical to apply ImmTOR technology to gene therapy programs for muscular dystrophies and other genetic diseases. The company's nanoparticles are engineered with precise sizes (typically 200-500 nanometers), controlled drug loading, and surface properties optimized for uptake by specific immune cell populations. Selecta has developed manufacturing processes producing clinical-grade ImmTOR nanoparticles at scales required for therapeutic applications, addressing a key challenge in nanomedicine translation. The company's approach represents sophisticated application of nanotechnology principles—using nanoparticle properties to program specific biological responses rather than simply delivering drugs. Selecta's clinical programs have generated important data on how synthetic nanoparticles can modulate human immune systems, contributing to fundamental understanding of nanoparticle immunology. As gene therapies and protein biologics become increasingly important in medicine, addressing immunogenicity challenges will be crucial for enabling repeat dosing and expanding patient populations. Selecta's ImmTOR platform offers a potentially broadly applicable solution to this critical problem, positioning the company at the intersection of nanomedicine and immunotherapy, two of the most promising areas in biopharmaceutical development.
NanoViricides
Shelton, United States
Developer of nanoviricide drugs designed to attack and destroy viruses
CytImmune Sciences
Rockville, United States
Developer of gold nanoparticle-based cancer therapeutics
Nanospectra Biosciences
Houston, United States
Developer of gold nanoshell-based thermal ablation therapy for cancer treatment
Nanobio Corporation
Ann Arbor, United States
Developer of nanoemulsion-based products for infection and vaccine delivery
Liquidia Technologies
Morrisville, United States
Developer of PRINT technology for precisely engineered drug particles
NanoMedical Systems
Austin, United States
Developer of nanochannel drug delivery implants for sustained therapeutic release
Nanosphere Health Sciences
Vancouver, Canada
Developer of NanoSphere Delivery System for enhanced bioavailability of cannabinoids
Tarveda Therapeutics
Watertown, United States
Developer of miniature drug conjugates for targeted cancer therapy
Arch Venture Partners
Chicago, United States
Venture capital firm focusing on early-stage technology companies including nanotech
NanoXact
San Diego, United States
Brand offering precisely manufactured nanoparticles for life science applications
Nanosonics
Sydney, Australia
Global leader in infection prevention with proprietary nanotechnology-based disinfection systems for medical devices
Moderna
Cambridge, United States
Pioneer in mRNA therapeutics using lipid nanoparticle (LNP) delivery technology for vaccines and medicines
BioNTech
Mainz, Germany
Immunotherapy company leveraging lipid nanoparticle delivery for mRNA vaccines and cancer therapies
Acuitas Therapeutics
Vancouver, Canada
Leading developer of lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, partner for COVID-19 vaccines
Precision NanoSystems
Vancouver, Canada
Provider of instruments for scalable nanoparticle manufacturing for gene therapies and mRNA vaccines
Alnylam Pharmaceuticals
Cambridge, United States
Pioneer in RNAi therapeutics using lipid nanoparticle delivery for treatment of genetic diseases
Intellia Therapeutics
Cambridge, United States
Gene editing company using lipid nanoparticle delivery for in vivo CRISPR therapeutics
Nanocure
Tel Aviv, Israel
Nanocure, established in 2015 in Tel Aviv, Israel, is an innovative nanomedicine company focused on developing next-generation cancer therapies through advanced nanoparticle-based drug delivery systems. The company's proprietary platform leverages the unique properties of engineered nanoparticles to achieve precise targeting of cancer cells while minimizing damage to healthy tissue, addressing one of the most significant challenges in oncology treatment. Nanocure's targeted nanoparticle therapeutics are designed to overcome the limitations of conventional chemotherapy, which often causes severe side effects due to non-selective distribution throughout the body. The company's nanoparticle formulations utilize sophisticated surface modifications, including targeting ligands and stealth coatings, to enhance circulation time, improve tumor accumulation through the enhanced permeability and retention effect, and facilitate active targeting to specific cancer cell markers. This multifaceted approach enables higher drug concentrations at tumor sites while reducing systemic exposure and associated toxicities. The technology platform is versatile, capable of encapsulating various therapeutic agents including small molecule drugs, peptides, and nucleic acids, making it applicable to multiple cancer types and treatment modalities. Nanocure's nanoparticles are engineered at the nanoscale (typically 10-200 nanometers) to optimize biological interactions, cellular uptake, and intracellular drug release. The company has secured over $15 million in funding to advance its pipeline through preclinical and clinical development stages. Israel's strong biotechnology ecosystem and expertise in nanomedicine provide Nanocure with access to world-class research facilities, clinical networks, and regulatory support. As cancer treatment increasingly moves toward personalized medicine and targeted therapies, Nanocure's nanoparticle platform represents a significant advancement in delivering more effective and safer cancer treatments, positioning the company as an important player in the rapidly evolving field of cancer nanotherapy.
Codiak BioSciences
Cambridge, United States
Codiak BioSciences, founded in 2015 in Cambridge, Massachusetts, is a pioneering biotechnology company at the forefront of exosome-based therapeutics. The company has developed the proprietary engEx platform, which engineers exosomes—naturally occurring nanovesicles (30-150 nanometers) secreted by cells—as sophisticated drug delivery vehicles. Unlike synthetic nanoparticles, exosomes offer inherent biocompatibility, low immunogenicity, and natural ability to cross biological barriers, making them ideal carriers for therapeutic payloads. Codiak's engEx technology precisely modifies exosomes to display specific targeting molecules on their surface while loading therapeutic cargo inside, creating programmable nanomedicines with enhanced tissue specificity and therapeutic efficacy. The company's lead programs include exoSTING, an exosome-delivered STING agonist for cancer immunotherapy, and exoIL-12, which delivers interleukin-12 for tumor treatment. These engineered exosomes leverage the body's natural intercellular communication system to deliver potent immunomodulatory agents directly to target cells, potentially revolutionizing cancer treatment with improved safety profiles compared to conventional delivery methods. Codiak has raised over $300 million in funding, reflecting significant investor confidence in exosome therapeutics. The Cambridge location places Codiak at the heart of the biotech innovation ecosystem, with access to world-renowned research institutions and clinical infrastructure. The company employs between 100-200 specialists in molecular biology, nanotechnology, and clinical development. Exosomes represent a convergence of cell biology and nanotechnology, and Codiak's platform addresses critical challenges in drug delivery including tumor penetration, immune evasion, and payload stability. As the field of nanomedicine evolves beyond synthetic nanoparticles, Codiak's focus on biological nanovesicles positions it as a leader in next-generation therapeutic delivery, with potential applications extending beyond oncology to neurodegenerative diseases, rare disorders, and vaccines.
Exosome Diagnostics
Waltham, United States
Exosome Diagnostics, founded in 2008 in Waltham, Massachusetts, emerged as a global leader in exosome-based liquid biopsy technology before being acquired by Bio-Techne Corporation. The company pioneered the use of exosomes—nanoscale extracellular vesicles (30-150 nm) naturally released by cells—as biomarkers for non-invasive disease detection and monitoring. Exosomes contain genetic material, proteins, and other molecular cargo that reflect the state of their cell of origin, making them valuable diagnostic tools for cancer and other diseases. Exosome Diagnostics developed sophisticated isolation and analysis technologies to capture these nanovesicles from bodily fluids and extract clinically relevant biomarkers, particularly RNA and DNA molecules. The company's flagship product, the ExoDx Prostate Test (IntelliScore), represents a breakthrough in prostate cancer detection, analyzing exosomal RNA from urine samples to help determine the need for prostate biopsy, thereby reducing unnecessary invasive procedures. This non-invasive approach leverages the natural biology of exosomes, which are shed into circulation and easily accessible through liquid biopsies. Exosome Diagnostics also developed comprehensive exosome isolation kits enabling researchers and clinicians to harness these nanosized vesicles for biomarker discovery and diagnostic applications. The company raised over $100 million in funding and established strategic partnerships with pharmaceutical companies and research institutions. The acquisition by Bio-Techne expanded the reach of exosome diagnostics technology within a larger life sciences organization. Exosome-based diagnostics represent a paradigm shift from traditional tissue biopsies to liquid biopsies, offering less invasive, repeatable testing that can track disease progression and treatment response. As precision medicine advances, exosome diagnostics continues to play a crucial role in enabling earlier disease detection, personalized treatment selection, and real-time monitoring, establishing exosomes as a transformative platform in nano-diagnostics and molecular medicine.
Nanexa
Uppsala, Sweden
Developer of PharmaShell nanocoating technology for controlled drug release
NanoVation Therapeutics
Vancouver, Canada
Developer of next-generation lipid nanoparticle delivery systems for RNA therapeutics
Verve Therapeutics
Boston, United States
Gene editing company using lipid nanoparticle delivery for cardiovascular disease treatment
Beam Therapeutics
Cambridge, United States
Pioneer in base editing using lipid nanoparticle delivery for precision genetic medicines
Sirnaomics
Gaithersburg, United States
Clinical-stage biopharmaceutical company developing RNAi therapeutics using polypeptide nanoparticle delivery
CureVac
Tubingen, Germany
Pioneer in mRNA technology using lipid nanoparticle delivery for vaccines and therapeutics
Genevant Sciences
Cambridge, United States
Developer of lipid nanoparticle and ligand conjugate delivery systems for genetic medicines
Arcturus Therapeutics
San Diego, United States
Developer of LUNAR lipid nanoparticle delivery platform for mRNA medicines
Silence Therapeutics
London, United Kingdom
Pioneer in precision RNAi medicines using mRNAi GOLD platform with GalNAc delivery
Dicerna Pharmaceuticals
Lexington, United States
Developer of GalXC RNAi platform for targeted gene silencing therapeutics
Nanobiotix SA
Cambridge, United States
Clinical-stage nanomedicine company developing first-in-class radioenhancers using hafnium oxide nanoparticles
NanoCarrier
Kashiwa, Japan
Developer of micellar nanoparticle drug delivery systems for cancer treatment
Nippon Kayaku
Tokyo, Japan
Pharmaceutical and chemical company with nanomedicine portfolio including micellar formulations
Starpharma Holdings
Melbourne, Australia
World leader in dendrimer nanotechnology for drug delivery and pharmaceutical applications
NanoMedSyn
Montpellier, France
Developer of MUSIC nanoparticle platform for targeted drug delivery
Nanovex Biotechnologies
Oviedo, Spain
Biotech company developing extracellular vesicle and exosome-based delivery systems
Nanovis
West Lafayette, United States
Developer of nanotube-reinforced polymer implants for orthopedic applications
Arrowhead Pharmaceuticals
Pasadena, United States
Leader in RNAi therapeutics using targeted delivery
Crystalplex
Pittsburgh, United States
Producer of quantum dots for biomedical imaging
Nanyang Technological University
Singapore, Singapore
Leading Asian university with strong nanotechnology research programs
Nanosphere Biosciences
Boulder, United States
Developer of nanobubble-based therapeutic delivery systems
NanoMedica
San Diego, United States
Developer of nanoparticle-based cancer therapeutics
NanoMed
Lancaster, United States
Developer of nanoscale surgical instruments
NanoPass Technologies
Ness Ziona, Israel
Developer of microneedle drug delivery systems
Nanoform Finland
Helsinki, Finland
Developer of controlled expansion of supercritical solutions for drug nanoforming
Translate Bio
Lexington, United States
mRNA therapeutics company with proprietary LNP technology, acquired by Sanofi
Etherna Immunotherapies
Niel, Belgium
mRNA immunotherapy company with proprietary LNP delivery technology
eTheRNA Immunotherapies
Niel, Belgium
mRNA immunotherapy with proprietary delivery platform
Strand Therapeutics
Boston, United States
Programmable mRNA therapeutics with logic gates
Mina Therapeutics
London, United Kingdom
Small activating RNA therapeutics with LNP delivery
Tidal Therapeutics
Cambridge, United States
LNP-based in vivo gene therapy for immune cells, acquired by Sanofi
ReNAgade Therapeutics
Cambridge, United States
RNA delivery technology for extrahepatic targets
NanoMedTrix
Berlin, Germany
Nanoparticle-based immunotherapy platform
Exicure
Chicago, United States
Spherical nucleic acid therapeutics platform
Nanox Imaging
Neve Ilan, Israel
Digital x-ray source using nanotechnology
SciSparc
Tel Aviv, Israel
Nano-drug delivery for CNS disorders
Nano Therapeutics
Mumbai, India
Nano-based drug delivery systems for cancer therapy
Khosla Ventures Nano
Menlo Park, United States
Major VC investor in nanotechnology startups
IMDEA Nanociencia
Madrid, Spain
Madrid's premier nanoscience research institute
NanoGune
San Sebastián, Spain
Nanoscience Cooperative Research Center
INL - International Iberian Nanotechnology Laboratory
Braga, Portugal
Iberian international nanotechnology research
Quantum-Si
Branford, United States
Single-molecule protein sequencing
NanoBio (BlueWillow Biologics)
Ann Arbor, United States
Nanoemulsion-based vaccines and therapeutics
NanoTherapeutics
Alachua, United States
Biopharmaceutical nanotechnology development
Ionis Pharmaceuticals
Carlsbad, United States
Antisense oligonucleotide therapeutics for genetic diseases
CRISPR Therapeutics
Zug, Switzerland
CRISPR-based gene editing therapeutics for blood disorders and cancer
Nanoform
Helsinki, Finland
Controlled expansion of supercritical solutions for drug nanoparticle engineering
Celgene (Bristol-Myers Squibb)
Summit, United States
Oncology and immunology therapeutics using nanoparticle formulations
Abraxis BioScience
Los Angeles, United States
Pioneer of nanoparticle albumin-bound (nab) technology for cancer drugs
NanoCarrier Co., Ltd.
Chiba, Japan
Polymeric micellar nanoparticle drug delivery for cancer therapeutics
Nanoparticle Dream
Tokyo, Japan
Quantum dot nanoparticles for biomedical imaging and diagnostics
LNP Japan
Tokyo, Japan
Lipid nanoparticle manufacturing services for RNA therapeutics
BioDynamics Laboratory
Tokyo, Japan
Nanogel and polymer technology for drug delivery applications
Starpharma
Melbourne, Australia
Dendrimer nanotechnology for antiviral and oncology therapeutics
NanoBio Corporation
Ann Arbor, United States
Nanoemulsion technology for intranasal vaccines and skin treatments
Nanospectra Biosciences
Houston, United States
Gold nanoshell photothermal ablation therapy for cancer
Nanobio2Pharma
Bordeaux, France
Nanoparticle drug formulation and CDMO services
NH TherAguix
Villeurbanne, France
Gadolinium-based nanoparticles for MRI-guided radiotherapy
Nanomerics
London, United Kingdom
Molecular envelope technology for enhanced drug delivery
Midatech Pharma
Abingdon, United Kingdom
Gold nanoparticle drug conjugates for oncology therapeutics
Ceramisphere
Sydney, Australia
Ceramic nanoparticle drug delivery systems
Camurus
Lund, Sweden
FluidCrystal lipid-based drug delivery systems
Ethris GmbH
Planegg, Germany
SNIM RNA stabilized mRNA therapeutics
Entos Pharmaceuticals
Edmonton, Canada
Fusogenix nucleic acid delivery platform
Arrowhead Pharmaceuticals
Pasadena, United States
TRiM RNAi therapeutics platform
Phio Pharmaceuticals
Marlborough, United States
INTASYL self-delivering RNAi technology
Nitto Denko Avecia
Milford, United States
Oligonucleotide and nucleic acid CDMO services
Ajinomoto Bio-Pharma Services
San Diego, United States
CDMO for oligonucleotides and ADCs
Takeda Pharmaceutical
Tokyo, Japan
Global pharma with nanomedicine programs
Astellas Pharma
Tokyo, Japan
Major pharma with nanotechnology drug delivery research
Daiichi Sankyo
Tokyo, Japan
Antibody-drug conjugates and nanomedicine oncology
Eisai Co.
Tokyo, Japan
Neurology and oncology with nanoformulation research
Shionogi & Co.
Osaka, Japan
Infectious disease pharma with nanoparticle research
Otsuka Pharmaceutical
Tokyo, Japan
CNS and oncology pharma with nanomedicine development
Sumitomo Pharma
Osaka, Japan
Regenerative medicine and nanomedicine programs
Chugai Pharmaceutical
Tokyo, Japan
Antibody engineering and innovative drug delivery
LG Chem Life Sciences
Seoul, South Korea
Life sciences division with nanoparticle drug delivery
Samyang Biopharmaceuticals
Seoul, South Korea
Genexol-PM polymeric micelle nanoparticle drugs
Celltrion
Incheon, South Korea
Biosimilars and antibody drug conjugates
Hanmi Pharmaceutical
Seoul, South Korea
LAPSCOVERY long-acting drug delivery platform
Yuhan Corporation
Seoul, South Korea
Korean pharma with nanoformulation programs
Daewoong Pharmaceutical
Seoul, South Korea
Innovative drug delivery and biologics
Hengrui Medicine
Lianyungang, China
Leading Chinese pharma with nanomedicine oncology programs
CSPC Pharmaceutical
Shijiazhuang, China
Major Chinese pharma with nanomedicine research
Hansoh Pharmaceutical
Lianyungang, China
Innovative Chinese pharma with nanoformulation expertise
Zhejiang Medicine
Shaoxing, China
API manufacturer with nano-formulation capabilities
WuXi AppTec
Shanghai, China
Global CRO/CDMO with nanomedicine manufacturing capabilities
Asymchem Laboratories
Tianjin, China
CDMO services including nanoparticle formulations
PharmaBlock Sciences
Nanjing, China
Building blocks and CDMO for nanomedicine synthesis
Livzon Pharmaceutical
Zhuhai, China
Chinese pharma with microsphere and nanoparticle delivery
Luye Pharma Group
Yantai, China
Advanced drug delivery including microspheres and liposomes
Taiwan Liposome Company
Taipei, Taiwan
BioSeizer and NanoX liposomal drug delivery platforms
PharmaEngine
Taipei, Taiwan
Liposomal formulations for cancer treatment
Celsion Corporation
Lawrenceville, United States
ThermoDox heat-activated liposomal doxorubicin
Oncobiologics
Cranbury, United States
Biosimilar development with advanced formulation technology
Sixfold Bioscience
London, United Kingdom
AI-driven nanoparticle delivery optimization
NanoSyrinx
Sheffield, United Kingdom
Bacterial contractile injection system for protein delivery
Nuvation Bio
New York, United States
Precision oncology with targeted drug development
Institute for Basic Science (IBS)
Daejeon, South Korea
Korean basic science institute with nano centers
ITRI (Industrial Technology Research Institute)
Hsinchu, Taiwan
Taiwan's largest applied research org with nano divisions
Nano4Imaging
Düsseldorf, Germany
Iron oxide nanoparticles for MRI contrast agents
National University of Singapore
Singapore, Singapore
Comprehensive nanotechnology research programs
Nano Biotecnologia SA
São Paulo, Brazil
Nanotechnology for cosmetic and pharmaceutical applications
University of São Paulo Nanomedicine
São Paulo, Brazil
Nanomedicine research at South America's largest university
Lonza
Basel, Switzerland
Life sciences and specialty ingredients
CR Micro
Wuxi, China
Power semiconductor foundry
Alnylam Pharmaceuticals
Cambridge, United States
Leader in RNAi therapeutics using lipid nanoparticle delivery for genetic diseases
Arbutus Biopharma
Vancouver, Canada
Develops lipid nanoparticle technology for hepatitis B and other infectious diseases
Arcturus Therapeutics
San Diego, United States
RNA medicines company using LUNAR lipid nanoparticle delivery platform
Acuitas Therapeutics
Vancouver, Canada
Develops lipid nanoparticle delivery systems for nucleic acid therapeutics
Genevant Sciences
Cambridge, United States
Lipid nanoparticle and ligand conjugate delivery platforms for genetic medicines
Intellia Therapeutics
Cambridge, United States
CRISPR gene editing company using lipid nanoparticle delivery for in vivo therapeutics
Verve Therapeutics
Cambridge, United States
Gene editing company for cardiovascular disease using base editing and LNP delivery
Ionis Pharmaceuticals
Carlsbad, United States
Pioneer in antisense technology and RNA-targeted therapeutics
Arrowhead Pharmaceuticals
Pasadena, United States
RNAi therapeutics company developing targeted delivery systems for genetic medicines
Dicerna Pharmaceuticals
Lexington, United States
RNAi therapeutics using GalXC delivery platform for liver-targeted gene silencing
Abbott Laboratories
Abbott Park, United States
Healthcare company with nanotechnology-based diagnostics and glucose monitoring
Senseonics
Germantown, United States
Implantable continuous glucose monitoring with fluorescent nanosensor technology
Medtronic
Dublin, Ireland
Medical device company with nanotechnology applications in implants and drug delivery
Boston Scientific
Marlborough, United States
Medical devices with nano-coated drug-eluting stents and implants
Edwards Lifesciences
Irvine, United States
Heart valve technologies with nano-engineered surfaces and coatings
Biotronik
Berlin, Germany
Cardiovascular devices with nanocoated stents and pacemaker leads
Abbott Vascular
Santa Clara, United States
Cardiovascular devices with drug-eluting nano-coated stents
Selecta Biosciences
Watertown, United States
ImmTOR biodegradable nanoparticles for immune tolerance induction
Celator Pharmaceuticals
Vancouver, Canada
Liposomal nanoparticle drug delivery for combination cancer therapies
NanOlogy
Fort Worth, United States
Submicron particle technology for localized drug delivery in cancer treatment
Halozyme Therapeutics
San Diego, United States
ENHANZE technology enabling subcutaneous delivery of biologics
Lipocine
Salt Lake City, United States
Lipid-based oral drug delivery platform for poorly bioavailable compounds
Liquidia Technologies
Morrisville, United States
PRINT nanoparticle technology for precisely engineered drug particles
Novavax
Gaithersburg, United States
Recombinant nanoparticle vaccine technology for infectious diseases
Vaxart
South San Francisco, United States
Oral vaccine platform using recombinant vectors and nanoparticle technology
Afrigen Biologics
Cape Town, South Africa
African mRNA vaccine hub developing lipid nanoparticle delivery technology
Serum Institute of India
Pune, India
World's largest vaccine manufacturer exploring nanoparticle vaccine technology
Bharat Biotech
Hyderabad, India
Vaccine developer with nanoparticle-based vaccine platforms
SK Bioscience
Seongnam, South Korea
Vaccine and biopharmaceutical company with nanoparticle vaccine capabilities
Quotient Sciences
Nottingham, United Kingdom
Drug development services including nanoparticle formulation technologies
Particle Sciences
Bethlehem, United States
Drug delivery and formulation development including nanoparticle systems
Catalent
Somerset, United States
Contract manufacturer with lipid nanoparticle and advanced drug delivery capabilities
Lonza Pharma
Basel, Switzerland
Life sciences company with lipid nanoparticle manufacturing for mRNA therapeutics
Evonik Health Care
Essen, Germany
Specialty chemicals for pharmaceutical drug delivery including lipid nanoparticles
Croda Health Care
Snaith, United Kingdom
Specialty ingredients including lipids for nanoparticle drug delivery
Curia Global
Albany, United States
Contract research and manufacturing with nanoparticle drug delivery expertise
Piramal Pharma Solutions
Mumbai, India
CDMO with capabilities in lipid nanoparticle and advanced drug delivery systems
Siegfried Holding
Zofingen, Switzerland
Pharmaceutical CDMO with particle engineering and formulation capabilities
Recipharm
Stockholm, Sweden
Contract manufacturer with inhaled nanoparticle and specialty drug delivery
Corden Pharma
Basel, Switzerland
CDMO specializing in lipids and lipid nanoparticle manufacturing
Exelead
Indianapolis, United States
CDMO focused on liposomes and lipid nanoparticle drug delivery systems
T&T Scientific
Knoxville, United States
Liposome and lipid nanoparticle preparation equipment and services
Polymun Scientific
Klosterneuburg, Austria
CDMO specializing in liposomal and lipid nanoparticle formulations
Encapsula NanoSciences
Brentwood, United States
Custom liposome and nanoparticle formulation services and products
FormuMax Scientific
Sunnyvale, United States
Liposome products and custom lipid nanoparticle formulation services
Northern Lipids
Vancouver, Canada
CDMO for liposomal and lipid nanoparticle drug delivery formulations
Lipoid GmbH
Ludwigshafen, Germany
Manufacturer of high-purity phospholipids for drug delivery and diagnostics
Avanti Polar Lipids
Alabaster, United States
High-purity lipids and liposomes for research and drug delivery applications
NOF Corporation
Tokyo, Japan
PEG-lipid conjugates and functional lipids for liposome drug delivery
Merck Life Science
Darmstadt, Germany
Life science products including lipids and nanomaterials for drug delivery research
nanoComposix
San Diego, United States
Engineered nanoparticles for biomedical, diagnostic, and research applications
Nanocs
New York, United States
PEGylation reagents and functionalized nanoparticles for biomedical applications
Beckman Coulter Diagnostics
Brea, United States
Clinical diagnostics with nanoparticle-based immunoassays and flow cytometry
Siemens Healthineers
Erlangen, Germany
Medical diagnostics with nanotechnology-based immunoassays and imaging agents
Hologic
Marlborough, United States
Molecular diagnostics with advanced detection technologies for women's health
Exact Sciences
Madison, United States
Cancer screening using molecular diagnostic and nanoparticle detection technologies
Singlera Genomics
Shanghai, China
DNA methylation-based early cancer detection and liquid biopsy
University of Tehran Nano
Tehran, Iran
Major Iranian university with nanomaterials and chemistry research
Bar-Ilan University Institute of Nanotechnology
Ramat Gan, Israel
University institute specializing in nanomedicine and nano-energy
National University of Singapore Nano
Singapore, Singapore
Top Asian university with comprehensive nanotechnology programs
Hong Kong University of Science and Technology
Hong Kong, Hong Kong
Research university with Institute for Advanced Study nanomaterials focus
Imperial College London Nano
London, United Kingdom
Leading UK university with London Centre for Nanotechnology
University College London Nano
London, United Kingdom
Major UK university with London Centre for Nanotechnology
NanoBright
Tempe, United States
Fluorescent nanoparticles for bioimaging applications
Evonik Health Care
Essen, Germany
Drug delivery polymers and lipid nanoparticle components
SES Research
Houston, United States
Fullerene production and carbon nanomaterials research
Alnylam Pharmaceuticals
Cambridge, United States
Pioneer in RNAi therapeutics with lipid nanoparticle delivery
Denali Therapeutics
South San Francisco, United States
Neurodegeneration drugs using Transport Vehicle BBB-crossing technology
Passage Bio
Philadelphia, United States
AAV gene therapies for CNS diseases with novel delivery
Voyager Therapeutics
Cambridge, United States
AAV capsid engineering for CNS gene therapy delivery
4D Molecular Therapeutics
Emeryville, United States
Therapeutic vectors using Directed Evolution AAV capsid discovery
Spark Therapeutics
Philadelphia, United States
Gene therapy pioneer (Luxturna) now part of Roche
Bluebird Bio
Somerville, United States
Gene therapy using lentiviral vectors for genetic diseases
LogicBio Therapeutics
Lexington, United States
Gene insertion technology using AAV and GeneRide platform
Generation Bio
Cambridge, United States
Non-viral gene therapy using lipid nanoparticle delivery
Stoke Therapeutics
Bedford, United States
Antisense oligonucleotides to upregulate protein expression
Dicerna Pharmaceuticals
Lexington, United States
RNAi therapeutics using GalNAc delivery (acquired by Novo Nordisk)
Curia Global
Albany, United States
CDMO with nanoparticle and complex formulation capabilities
Croda International
Snaith, United Kingdom
Specialty chemicals with Avanti lipids for LNP formulations
Entos Pharmaceuticals
Edmonton, Canada
Fusogenix DNA delivery platform for gene therapy
Kernal Biologics
Cambridge, United States
Self-amplifying mRNA with immune-silent delivery
Replicate Bioscience
San Diego, United States
Self-replicating RNA therapeutics platform
Laronde
Cambridge, United States
Endless RNA (eRNA) technology for persistent protein expression
Orna Therapeutics
Cambridge, United States
Circular RNA platform for cell therapy and protein replacement
Chimeron Bio
Philadelphia, United States
Chimeric viral vectors for improved gene therapy delivery
Entrada Therapeutics
Boston, United States
Endosomal Escape Vehicle (EEV) platform for intracellular delivery
Bicycle Therapeutics
Cambridge, United Kingdom
Bicyclic peptide platform for targeted drug delivery
PeptiDream
Kawasaki, Japan
Peptide Drug Discovery Platform System for macrocyclic therapeutics
Sorrento Therapeutics
San Diego, United States
Biopharmaceutical with ADC and nanoparticle delivery platforms
Mersana Therapeutics
Cambridge, United States
Antibody drug conjugates using Dolasynthen platform
ADC Therapeutics
Lausanne, Switzerland
Antibody drug conjugates for hematological malignancies
Seagen
Bothell, United States
ADC pioneer (Adcetris, Padcev) acquired by Pfizer
ImmunoGen
Waltham, United States
ADC technology company acquired by AbbVie
Synaffix
Amsterdam, Netherlands
ADC technology platform using GlycoConnect and toxSYN
Abzena
Cambridge, United Kingdom
ADC development and manufacturing CDMO
Sutro Biopharma
South San Francisco, United States
Cell-free protein synthesis for site-specific ADC conjugation
Bioasis Technologies
Guilford, Canada
xB3 platform for blood-brain barrier crossing drug delivery
AngioChem
Montreal, Canada
Peptide-drug conjugates for CNS delivery across BBB
Annexon Biosciences
Brisbane, United States
Complement cascade inhibitors for neurological diseases
Prevail Therapeutics
New York, United States
Gene therapies for neurodegenerative diseases (Eli Lilly)
Sangamo Therapeutics
Brisbane, United States
Zinc finger nuclease gene editing and gene regulation
Applied Genetic Technologies
Alachua, United States
AAV gene therapies for rare ophthalmologic diseases
Regenxbio
Rockville, United States
AAV gene therapy using NAV Technology Platform
MeiraGTx
New York, United States
Gene therapy for inherited retinal diseases and beyond
Krystal Biotech
Pittsburgh, United States
Gene therapies using HSV-1 vectors for skin diseases
Sarepta Therapeutics
Cambridge, United States
Gene therapy and RNA therapeutics for muscular dystrophies
Solid Biosciences
Charlestown, United States
Gene therapy for Duchenne muscular dystrophy
Ultragenyx Pharmaceutical
Novato, United States
Gene therapy and biologics for rare genetic diseases
Rocket Pharmaceuticals
Cranbury, United States
Lentiviral and AAV gene therapies for rare diseases
Genethon
Evry, France
Non-profit gene therapy research laboratory
Lysogene
Paris, France
CNS-targeted gene therapy for lysosomal storage diseases
Freeline Therapeutics
Stevenage, United Kingdom
AAV gene therapy for liver-targeted diseases
Orchard Therapeutics
London, United Kingdom
Hematopoietic stem cell gene therapy for rare diseases
Poseida Therapeutics
San Diego, United States
Gene editing and CAR-T cell therapy using piggyBac system
Precision BioSciences
Durham, United States
ARCUS genome editing for cell therapy and gene correction
Cellectis
Paris, France
TALEN gene editing for allogeneic CAR-T cell therapy
Carisma Therapeutics
Philadelphia, United States
CAR-Macrophage therapy for solid tumors
Fate Therapeutics
San Diego, United States
iPSC-derived cell therapies including NK and T cells
Ultragenyx Pharmaceutical
Novato, United States
Biopharmaceutical company developing novel products for rare and ultra-rare diseases
Biomarin Pharmaceutical
San Rafael, United States
Global biotechnology company developing therapies for rare genetic diseases
Vertex Pharmaceuticals
Boston, United States
Global biotechnology company focused on cystic fibrosis and gene editing therapies
Kite Pharma
Santa Monica, United States
Cell therapy company developing engineered autologous CAR T-cell cancer immunotherapies
Bristol Myers Squibb Cell Therapy
Summit, United States
Global biopharmaceutical company with leading CAR T cell therapy franchise
Legend Biotech
Somerset, United States
Global biotechnology company developing novel cell therapies for oncology
Allogene Therapeutics
South San Francisco, United States
Clinical-stage biotechnology company pioneering allogeneic CAR T cell therapies
Lyell Immunopharma
South San Francisco, United States
T cell reprogramming company developing next-generation cell therapies for solid tumors
Adicet Bio
Menlo Park, United States
Clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies
Takeda Cell Therapy
Tokyo, Japan
Global pharmaceutical company with advanced cell therapy programs
Daiichi Sankyo ADC
Tokyo, Japan
Global pharmaceutical company with leading ADC technology platform
Exelixis
Alameda, United States
Oncology company developing transformative cancer treatments
Lonza Cell and Gene
Basel, Switzerland
Global CDMO providing cell and gene therapy manufacturing services
Catalent Cell and Gene
Somerset, United States
Global CDMO offering cell therapy, gene therapy, and viral vector manufacturing
WuXi Advanced Therapies
Shanghai, China
Global contract development and manufacturing organization for advanced therapies
Oxford Biomedica
Oxford, United Kingdom
Gene and cell therapy group specializing in lentiviral vector development and manufacturing
uniQure
Amsterdam, Netherlands
Gene therapy company developing AAV-based treatments for severe genetic diseases
Rocket Pharmaceuticals
Cranbury, United States
Gene therapy company developing treatments for rare childhood diseases
Asklepios BioPharmaceutical
Research Triangle Park, United States
Gene therapy company developing AAV-based treatments for genetic diseases
Abeona Therapeutics
New York, United States
Clinical-stage biopharmaceutical company developing gene therapies for rare diseases
LogicBio Therapeutics
Lexington, United States
Genome editing company developing gene insertion medicines for pediatric diseases
Lexeo Therapeutics
New York, United States
Gene therapy company developing treatments for cardiac and neurological diseases
Neurogene
New York, United States
Gene therapy company developing treatments for rare neurological diseases in children
Sana Biotechnology
Seattle, United States
Biotechnology company engineering cells to treat disease using in vivo and ex vivo approaches
Taysha Gene Therapies
Dallas, United States
Gene therapy company developing treatments for monogenic CNS diseases
Abbott Laboratories
Abbott Park, United States
Global healthcare company with diagnostics and medical device solutions
Becton Dickinson
Franklin Lakes, United States
Global medical technology company advancing the world of health
Insulet Corporation
Acton, United States
Medical device company developing tubeless insulin pump technology
Tandem Diabetes Care
San Diego, United States
Medical device company developing advanced insulin pump technology
GE HealthCare
Chicago, United States
Medical technology company providing imaging, monitoring, and diagnostics solutions
Philips Healthcare
Amsterdam, Netherlands
Health technology company focused on improving health through innovation
Canon Medical Systems
Otawara, Japan
Medical imaging company developing CT, MRI, X-ray, and ultrasound systems
Varian Medical Systems
Palo Alto, United States
Medical device company focused on radiation oncology treatments
Elekta
Stockholm, Sweden
Medical technology company developing precision radiation medicine
Baxter International
Deerfield, United States
Healthcare company focused on products for hospitalized patients
Olympus Medical
Tokyo, Japan
Precision technology company with leading endoscopy and surgical solutions
Karl Storz
Tuttlingen, Germany
Medical device company developing endoscopes and imaging systems
Accuray
Sunnyvale, United States
Radiation oncology company developing precise cancer treatment systems
Nevro
Redwood City, United States
Medical device company developing high-frequency spinal cord stimulation therapy
Axonics
Irvine, United States
Medical technology company developing rechargeable sacral neuromodulation systems
LivaNova
London, United Kingdom
Medical technology company focused on neuromodulation and cardiopulmonary
NeuroPace
Mountain View, United States
Medical device company developing responsive neurostimulation for epilepsy
Penumbra
Alameda, United States
Medical device company developing innovative therapies for vascular conditions
MicroPort Scientific
Shanghai, China
Global medical device company with diverse portfolio across therapeutic areas
Resmed
San Diego, United States
Medical device company developing products for sleep apnea and respiratory care
Masimo
Irvine, United States
Medical technology company developing noninvasive patient monitoring solutions
ABIOMED
Danvers, United States
Medical device company developing heart recovery technologies
AtriCure
Mason, United States
Medical device company developing surgical treatments for atrial fibrillation
Shockwave Medical
Santa Clara, United States
Medical device company developing intravascular lithotripsy technology
Inspire Medical Systems
Maple Grove, United States
Medical technology company developing implantable neurostimulation for sleep apnea
TransMedics
Andover, United States
Medical technology company developing organ care system for transplantation
Senseonics Holdings
Germantown, United States
Medical technology company developing implantable continuous glucose monitoring
AngioDynamics
Latham, United States
Medical device company developing minimally invasive medical devices
ICU Medical
San Clemente, United States
Medical device company developing infusion therapy and critical care products
Teleflex
Wayne, United States
Medical technology company developing devices for critical care and surgery
Haemonetics
Boston, United States
Global healthcare company providing blood management solutions
Merit Medical
South Jordan, United States
Medical device company manufacturing products for interventional procedures
Butterfly Network
Burlington, United States
Medical device company developing handheld whole-body ultrasound
Nanox
Neve Ilan, Israel
Medical imaging company developing novel digital X-ray source technology
Oscar Health
New York, United States
Technology-focused health insurance company with member-centric approach
SEGA Sammy Holdings
Tokyo, Japan
Japanese gaming company known for Sonic and arcade games
Alan
Paris, France
Digital health insurance company in Europe
Spotify
Stockholm, Sweden
Leading audio streaming platform for music and podcasts
Varda Space Industries
El Segundo, United States
Space manufacturing and re-entry capsules
BIMA
Stockholm, Sweden
Mobile insurance for emerging markets
Calibrate
New York, United States
Metabolic health company
Spectradyne
Signal Hill, United States
Nanoparticle Analyzer based on microfluidic resistive pulse sensing
pSivida (Eyepoint)
Watertown, United States
Sustained ocular drug delivery
nanoTherics
Newcastle upon Tyne, United Kingdom
Magnetic nanoparticle research tools
Nanopass Technologies
Ness Ziona, Israel
Microneedle technology for intradermal drug delivery
Nanomi
Oldenzaal, Netherlands
Membrane emulsification for nanoparticle production
NanoString Technologies
Seattle, United States
Molecular barcode technology for gene expression analysis
INL - International Iberian Nanotechnology
Braga, Portugal
International nanotechnology laboratory in Europe
NanoGune
San Sebastián, Spain
Basque nanoscience research center
INBRAIN Neuroelectronics
Barcelona, Spain
Advanced neural interfaces from graphene for therapeutic brain-computer applications
QDI Systems
Eindhoven, Netherlands
Quantum dots technology for X-ray imaging and mammography screening
ARIZ Precision Medicine
San Diego, United States
Nanotechnology for targeted cancer drug delivery using siRNA nanoparticles
SeraGene Therapeutics
London, United Kingdom
RNA and nanomedicine treatments for blood disorders
Nanoligent
Leuven, Belgium
Oncology nanodrug development
Madrigal Mental Care
Boston, United States
Organic nanoparticle drug delivery for mental health
Theranautilus
Bangalore, India
Nanobots for dental healthcare and root canal disinfection
Aurora Biosynthetics
Singapore, Singapore
GMP manufacturing of plasmid DNA, mRNA and lipid nanoparticles for Asia Pacific
Mepsgen
Seoul, South Korea
NanoCalibur automated nanoparticle production using microfluidic technology
Exsilio Therapeutics
Boston, United States
mRNA platform for revocable genetic medicines
Nanobiotec
Madrid, Spain
Nanomedicine and drug delivery solutions
Cour Pharmaceutical
Chicago, United States
Particle platforms enabling immune targeting for inflammatory and immune applications
Zylo Therapeutics
Minneapolis, United States
Sustained-release drug-delivery system using hydrogel-derived nanoparticles
iCeutica
Sydney, Australia
Encapsulated Organic Nanoparticles (EON) platform for nano-sized drug particles
Helex
Boston, United States
Lipid nanoparticle technology for targeted drug delivery for kidney diseases
NuVascular Technologies
Minneapolis, United States
Next-generation devices for end-stage renal disease treatment
Bio-Gate
Nuremberg, Germany
Silver nanotechnology for antimicrobial medical products and consumer goods
Meda Biotech
Shanghai, China
Hybrid-nanoengineered water soluble drugs optimizing drug trafficking to disease sites
DNA Nanobots
Cambridge, United States
DNA-based nanodevices for targeted therapeutics delivery, vaccines, and diagnostics
Avisi Technologies
San Diego, United States
VisiPlate nanotechnology-enabled ocular implant for glaucoma treatment
NanoFCM
Nottingham, United Kingdom
Flow nano analyzer for high-resolution nanoparticle characterization
Revalesio Corporation
Tacoma, United States
Oxygen delivery technology at nano-scale for therapeutic applications
Mulder Lab
Eindhoven, Netherlands
Nanomedicine research and development services
Nano4Tarmed
Coimbra, Portugal
Nanotechnology platforms for targeted medicine and cancer treatment
Robeauté
Paris, France
Modular swallowable microrobots for targeted medical interventions
Sona Nanotech
Halifax, Canada
Non-toxic gold nanorods for photothermal therapy and tumor-targeting drug delivery
Blueberry Therapeutics
Manchester, United Kingdom
Polymer nanoparticles for treating fungal infections with 83% efficacy
Cello Therapeutics
San Diego, United States
Cell membrane-coated nanoparticles for immunotherapy delivery with FDA IND status
Adocia
Lyon, France
BioChaperone nanoformulation technology for improved insulin delivery
Natural Immunogenics
Sarasota, United States
Colloidal silver nanoparticle products for antimicrobial applications
Silversol
Salt Lake City, United States
Silver nanoparticle technology for wound care and antimicrobial applications
Nanocare
Mumbai, India
Silver nanoparticle antimicrobial coatings for textiles and medical applications
HK Inno.N
Seoul, South Korea
Pharmaceutical nanotechnology for drug delivery systems
Neocis
Miami, United States
Robotic systems with nano-precision for dental implant procedures
Inosep
Seoul, South Korea
Polymer nanofiltration membranes for water treatment and desalination
Evox Therapeutics
Oxford, United Kingdom
DeliverEX platform for engineered exosome therapeutics
Aruna Bio
Athens, United States
Neural-derived exosomes for CNS drug delivery crossing BBB
ExonanoRNA
Boston, United States
RNA nanoparticles and exosomes for cancer therapeutics
Phosphorex
Hopkinton, United States
CDMO for lipid nanoparticle and liposome drug delivery
DIVERSA Technologies
Santiago de Compostela, Spain
Innovative nanoparticle formulations for drug delivery
MagForce
Berlin, Germany
Magnetic nanoparticle hyperthermia therapy for brain tumors
Imagion Biosystems
Sydney, Australia
MagSense magnetic nanoparticle detection for cancer diagnostics
Nanordica Medical
Tartu, Estonia
Silver and copper nanoparticle wound care products